» Articles » PMID: 36320450

Living HTA: Automating Health Economic Evaluation with R

Overview
Date 2022 Nov 3
PMID 36320450
Authors
Affiliations
Soon will be listed here.
Abstract

Requiring access to sensitive data can be a significant obstacle for the development of health models in the Health Economics & Outcomes Research (HEOR) setting. We demonstrate how health economic evaluation can be conducted with minimal transfer of data between parties, while automating reporting as new information becomes available. We developed an automated analysis and reporting pipeline for health economic modelling and made the source code openly available on a GitHub repository. The pipeline consists of three parts: An economic model is constructed by the using pseudo data. On the data-owner side, an application programming interface (API) is hosted on a server. This API hosts all sensitive data, so that data does not have to be provided to the . An automated workflow is created, which calls the API, retrieves results, and generates a report. The application of modern data science tools and practices allows analyses of data without the need for direct access - negating the need to send sensitive data. In addition, the entire workflow can be largely automated: the analysis can be scheduled to run at defined time points (e.g. monthly), or when triggered by an event (e.g. an update to the underlying data or model code); results can be generated automatically and then be exported into a report. Documents no longer need to be revised manually. This example demonstrates that it is possible, within a HEOR setting, to separate the health economic model from the data, and automate the main steps of the analysis pipeline.

Citing Articles

Comparison of health-related quality of life in atopic dermatitis, hidradenitis suppurativa, pemphigus and psoriasis.

Balazs P, Gaspar K, Gergely H, Hajdu K, Hollo P, Koszoru K Arch Dermatol Res. 2025; 317(1):291.

PMID: 39825944 PMC: 11742771. DOI: 10.1007/s00403-024-03786-4.


A Framework for Using Cost-effectiveness Analysis to Support Pricing and Reimbursement Decisions for New Pharmaceuticals in a Context of Evolving Treatments, Prices, and Evidence.

Woods B, Palacios A, Sculpher M Pharmacoeconomics. 2024; .

PMID: 39739218 DOI: 10.1007/s40273-024-01450-3.


Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review.

Grand T, Ren S, Hall J, Astrom D, Regnier S, Thokala P Pharmacoeconomics. 2024; 42(6):619-631.

PMID: 38616217 PMC: 11126517. DOI: 10.1007/s40273-024-01370-2.


Improving the usability of open health service delivery simulation models using Python and web apps.

Monks T, Harper A NIHR Open Res. 2023; 3:48.

PMID: 37881450 PMC: 10593330. DOI: 10.3310/nihropenres.13467.1.


Living health technology assessments: how close to living reality?.

Sarri G, Forsythe A, Elvidge J, Dawoud D BMJ Evid Based Med. 2023; 28(6):369-371.

PMID: 36797052 PMC: 10715551. DOI: 10.1136/bmjebm-2022-112152.

References
1.
Smith R, Schneider P . Making health economic models Shiny: A tutorial. Wellcome Open Res. 2020; 5:69. PMC: 7459889. DOI: 10.12688/wellcomeopenres.15807.2. View

2.
McCabe C, Paulden M, Awotwe I, Sutton A, Hall P . One-Way Sensitivity Analysis for Probabilistic Cost-Effectiveness Analysis: Conditional Expected Incremental Net Benefit. Pharmacoeconomics. 2019; 38(2):135-141. PMC: 6977148. DOI: 10.1007/s40273-019-00869-3. View

3.
Alarid-Escudero F, Krijkamp E, Enns E, Yang A, Hunink M, Pechlivanoglou P . A Tutorial on Time-Dependent Cohort State-Transition Models in R Using a Cost-Effectiveness Analysis Example. Med Decis Making. 2022; 43(1):21-41. PMC: 9844995. DOI: 10.1177/0272989X221121747. View

4.
Brennan A, Kharroubi S, OHagan A, Chilcott J . Calculating partial expected value of perfect information via Monte Carlo sampling algorithms. Med Decis Making. 2007; 27(4):448-70. DOI: 10.1177/0272989X07302555. View

5.
Pouwels X, Sampson C, Arnold R . Opportunities and Barriers to the Development and Use of Open Source Health Economic Models: A Survey. Value Health. 2022; 25(4):473-479. DOI: 10.1016/j.jval.2021.10.001. View